Cadence Pharmaceuticals, Inc. (CADX) Posts Slightly Wide Loss of 28c Share

Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) reported Q4 EPS of ($0.28), $0.01 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $6.88 million.

For earnings history and earnings-related data on Cadence Pharmaceuticals, Inc. (CADX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Jaguar Health (JAGX) Tops Q2 EPS by 3647c
• FOMC minutes from July 28-29th meeting